Lymphoproliferative Disorders clinical trials

The registry lists 216 studies for Lymphoproliferative Disorders across more than 10 countries. 49 are recruiting or about to start. 34 of them are mainly about Lymphoproliferative Disorders (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its 53 narrower conditions too, such as Multiple Myeloma: 15,145 studies, 3,324 open.

Get an email when these change. Save the Lymphoproliferative Disorders studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 88
Recruiting: 39
Terminated: 35
Active, not recruiting: 22
Status unknown: 11
Withdrawn: 9

Phase

Phase 2: 98
Phase 1: 67
Phase 3: 27
Phase 4: 2
Early Phase 1: 2

Where

United States: 147
France: 26
Italy: 24
Germany: 24
United Kingdom: 22
Spain: 18

Who runs them

National Cancer Institute (NCI) (12) · Baylor College of Medicine (9) · Seagen Inc. (7) · National Institute of Allergy and Infectious Diseases (NIAID) (6) · Cancer Research UK (6) · UNC Lineberger Comprehensive Cancer Center (5) · M.D. Anderson Cancer Center (5) · Mayo Clinic (5)

What is being tested here

Drugs under test in Lymphoproliferative Disorders studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Pacritinib	2	0	3
Dabrafenib	2	2	2
Trametinib	2	2	2
Alectinib	2	2	2
Atezolizumab	2	2	2
Entrectinib	2	2	2
Cyclophosphamide	1	0	10
Prednisone	1	0	4
Etoposide	1	0	2
Doxorubicin	1	0	2

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · Immune checkpoint inhibitors 3 open · Alkylating agents 1 open · Corticosteroids 1 open · Antimetabolites 14

Coming up

7phase 3 studies under way

18studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Feb 2027A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) · Phase 3 · Acerta Pharma BV
Dec 2026A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL · Georgetown University
Dec 2026A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · OriCell Therapeutics Co., Ltd.
Dec 2026HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis · Center for International Blood and Marrow Transplant Research
Dec 2026Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders · Timothy Voorhees
Mar 2027A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma · Kelonia Therapeutics, Inc.
Mar 2027Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE · Baylor College of Medicine
Apr 2027Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Jennifer Amengual
May 2027Ultrasound to Detect Splenomegally in Patients With Isolated Thrombocytopenia · Assiut University
Jun 2027A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases · Pierre Fabre Medicament

Who these studies take

Of the 39 Lymphoproliferative Disorders studies recruiting now, 28 (72%) set no upper age limit and 6 (15%) stop at 75 or younger. 18 (46%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 2 (5%) take healthy volunteers.

Recruiting studies that take each age, of 39
Age	Women	Men
10	15 (38%)	15 (38%)
18	38 (97%)	38 (97%)
30	37 (95%)	37 (95%)
40	37 (95%)	37 (95%)
50	37 (95%)	37 (95%)
65	38 (97%)	38 (97%)
75	36 (92%)	36 (92%)
85	33 (85%)	33 (85%)

Across all 216 studies, recruiting or not: 24% stop at 75 or younger and 15% at 65; 39% take children; 0% are for women only and 0% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Lymphoproliferative Disorders studies take

Of 30 phase 2 interventional studies under Lymphoproliferative Disorders, half reached primary completion within 144 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	144 mo57–356 · 30 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Results posted1

Immune Disorder HSCT ProtocolOct 27, 2026NCT01821781

Studies

Recruiting first, then most recently updated. Showing 50 of 216. Browse all 216 → or search them.